[#item_full_content] Medical cannabis’s cultivar names have, over the past two years, become an increasingly controversial part of the European prescription framework. In the UK, the Medicines and Healthcare Products Regulatory Agency (MHRA) has been quietly raising concerns with clinicians and clinics over the ‘recreational’ brand names common throughout the European medical market. As James Duckenfield, CEO  Read More